My watch list  


Therapeutic monoclonal antibody
Source Humanized
Target Complement protein C5
CAS number 219685-50-4
ATC code L04AA25
PubChem  ?
Chemical data
Formula  ?
Mol. mass 148 kDa
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life 8 to 15 days (mean 11 days)
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status


Routes Intravenous infusion

Eculizumab (rINN and USAN, trade name Soliris) is a monoclonal antibody directed against the complement protein C5. This antibody blocks the cleavage of C5 and halts the process of complement-mediated cell destruction. Eculizumab is a product of Alexion Pharmaceuticals and has been shown to be effective in treating paroxysmal nocturnal hemoglobinuria.[1] Eculizumab was approved by the United States Food and Drug Administration (FDA) on March 16, 2007.

Ecuilzumab exibits it's theraputic activity by bind to the 2b subunit of the C5 convertase enzyme. C5 convertase is produced by the binding of subunits C4b,C2b and C3b on the surface of the bacterium. Binding of Eculizumab to the 2b subunit, results in the reduction of the esterase activity of this subunit, therefore C5 convertase cannot hydrolysize C5 into C5a & C5b subunits respectively.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Eculizumab". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE